Other studies have identified pharmacological interventions that prevent hyperalgesia development if CCL2 is neutralized prior to the neuropathic induction [12] giving insight into an eventual CCR2-mediated treatment for neuropathic pain. The gene discussed is CCR2; the disease is neuropathic pain.